Mark W. Hahn, Chief Financial Officer at Verona Pharma plc (VRNA), sold 285,920 shares at $4.38 ($1.3M) on 2024-10-24, disclosed to the SEC on 2024-10-25.
Scheduled sale ($1.3M) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $4.38 | 141,360 | $619K | 49.4% |
| 2 | $4.38 | 141,360 | $619K | 49.4% |
| 3 | $4.38 | 3,200 | $14K | 1.1% |
| Total | $4.38 avg | 285,920 | $1.3M | 100% |
| Filing → |
| VRNA | SELL | 2025-05-29 | $7.5M | — | Filing → |
| VRNA | SELL | 2025-05-05 | $7.0M | — | Filing → |
| VRNA | SELL | 2025-05-01 | $1.6M | — | Filing → |